Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 1
2004 2
2005 1
2008 3
2009 1
2012 1
2015 3
2016 3
2019 1
2020 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. Blauvelt A, et al. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15. Br J Dermatol. 2020. PMID: 31887225 Free PMC article. Clinical Trial.
Natural rubber latex allergy.
Kahn SL, Podjasek JO, Dimitropoulos VA, Brown CW Jr. Kahn SL, et al. Among authors: dimitropoulos va. Dis Mon. 2016 Jan;62(1):5-17. doi: 10.1016/j.disamonth.2015.11.002. Epub 2015 Dec 29. Dis Mon. 2016. PMID: 26743990 Review. No abstract available.
Dermatofibrosarcoma protuberans.
Dimitropoulos VA. Dimitropoulos VA. Dermatol Ther. 2008 Nov-Dec;21(6):428-32. doi: 10.1111/j.1529-8019.2008.00242.x. Dermatol Ther. 2008. PMID: 19076619
Conjunctival papilloma.
Litak J, Dimitropoulos VA, Dy LC, Brown CW, Grostern RJ. Litak J, et al. Among authors: dimitropoulos va. Cutis. 2012 Jan;89(1):38-40. Cutis. 2012. PMID: 22439310
Reasons behind the ink.
Dimitropoulos V, Brown CW Jr, Ressa NA, Newman M. Dimitropoulos V, et al. Cutis. 2016 Nov;98(5):320-322. Cutis. 2016. PMID: 28040806
Forehead donor site full-thickness skin graft.
Dimitropoulos V, Bichakjian CK, Johnson TM. Dimitropoulos V, et al. Dermatol Surg. 2005 Mar;31(3):324-6. doi: 10.1111/j.1524-4725.2005.31082. Dermatol Surg. 2005. PMID: 15841635 Free article.
Keeping Our Classification UP to Date.
Doyle K, Dimitropoulos V. Doyle K, et al. Among authors: dimitropoulos v. Health Inf Manag. 2009 Mar;38(1):50-52. doi: 10.1177/183335830903800107. Health Inf Manag. 2009. PMID: 28758496
19 results